Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations

Annals of Clinical Biochemistry

Volumn 53, Issue 4, 2016, Pages 446-451

  Božič Mijovski, Mojca ^a   Malmström, Rickard E ^b   Malovrh, Petra ^a   Antovic, Jovan P ^b   Vene, Nina ^a   Šinigoj, Petra ^a   Mavri, Alenka ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

clinical laboratory techniques; Dabigatran; thrombin time

Indexed keywords

DABIGATRAN; THROMBIN; THROMBIN INHIBITOR; ANTITHROMBIN;

ARTICLE; ATRIAL FIBRILLATION; BLOOD ANALYSIS; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTED THROMBIN TIME; DRUG BLOOD LEVEL; EX VIVO STUDY; HUMAN; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MEASUREMENT ACCURACY; PRIORITY JOURNAL; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; THROMBIN TIME; AGED; BLOOD; DRUG MONITORING; LIMIT OF DETECTION;

AGED; ANTITHROMBINS; DABIGATRAN; DRUG MONITORING; HUMANS; LIMIT OF DETECTION; REPRODUCIBILITY OF RESULTS; THROMBIN TIME;

EID: 84971401619     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563215599795     Document Type: Article

References (15)

1. J.Stangier. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet2008; 47: 285–295.
2. T.BaglinA.HillarpA.Tripodi. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost2013; 11: 756–760.
3. J.P.AntovicM.SkeppholmJ.Eintrei. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol2013; 69: 1875–1881.
4. E.M.H.SchmitzD.van den HeuvelK.Boonen. Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring. Ned Tijdschr Klin Chem Labgeneesk2013; 38: 142–144.
5. J.StangierK.RathgenH.Stahle. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol2007; 64: 292–303.
6. J.van RynJ.StangierS.Haertter. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost2010; 103: 1116–1127.
7. J.DouxfilsJ.M.DogneF.Mullier. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost2013; 110: 543–549.
8. Šinigoj P, Malmström RE, Vene N, et al. Dabigatran concentration: variability and potential bleeding prediction in real-life patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. Epub ahead of print 15 May 2015. DOI: 10.1111/bcpt.12417
9. IUPAC. Compendium of chemical terminology (the “Gold Book”), 2nd ed. Oxford, UK: Blackwell Scientific Publications, 1997.
10. J.StangierM.Feuring. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis2012; 23: 138–143.
11. E.M.SchmitzK.BoonenD.J.van den Heuvel. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography – tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost2014; 12: 1636–1646.
12. S.T.AvecillaC.FerrellW.L.Chandler. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol2012; 137: 572–574.
13. J.DouxfilsS.LessireA.S.Dincq. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost2014; 113: 862–869.
14. S.D.JonesN.S.EaddyG.T.Chan. Dabigatran: laboratory monitoring. Pathology2012; 44: 578–580.
15. M.SkeppholmP.HjemdahlJ.P.Antovic. On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation. Thromb Res2014; 134: 783–789.